Epidiolex, a plant-derived cannabidiol (CBD) with no mind-altering effects, has been approved by Japanese Ministry of Health, Labor and Welfare for clinical trials in epileptic patients with Dravet and Lennox-Gastaut Syndromes. Japan does prohibit cannabis-based...